A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.
about
Glucocorticoids for acute viral bronchiolitis in infants and young childrenGlucocorticoids for acute viral bronchiolitis in infants and young childrenSteroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysisCan the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?Glucocorticoid-independent modulation of GR activity: Implications for immunotherapyPotential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseasesCan the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?Effect of switching to a high-deductible health plan on use of chronic medicationsEffect of combined dexamethasone therapy with nebulized r-epinephrine or salbutamol in infants with bronchiolitis: A randomized, double-blind, controlled trial.Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.β₂ AR agonists in treatment of chronic heart failure: long path to translation.Long-acting β2-agonists increase fluticasone propionate-induced mitogen-activated protein kinase phosphatase 1 (MKP-1) in airway smooth muscle cells.Glucocorticosteroids: current and future directions.β2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoidsCorticosteroids and β₂-agonists upregulate mitogen-activated protein kinase phosphatase 1: in vitro mechanismsEfficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment.RETRACTED: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?Pharmacotherapy of asthma: regular treatment or on demand?Agonist efficacy and receptor desensitization: from partial truths to a fuller picture.Mitochondria in lung diseases.Epithelial cells and airway diseases.Corticosteroids in respiratory diseases in children.cAMP regulation of airway smooth muscle function.Multiple facets of cAMP signalling and physiological impact: cAMP compartmentalization in the lung.Orally inhaled fixed-dose combination products for the treatment of asthma and chronic obstructive pulmonary disease: not simple math.Evaluation of the efficacy and safety of a fixed-dose, single-capsule budesonide-formoterol combination in uncontrolled asthma: a randomized, double-blind, multicenter, controlled clinical trial.Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Epinephrine and Corticosteroid Therapy for Acute Bronchiolitis in Infants.Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.Cytokine-induced loss of glucocorticoid function: effect of kinase inhibitors, long-acting β(2)-adrenoceptor [corrected] agonist and glucocorticoid receptor ligands.Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.Beta-Adrenergic AgonistsThe long-acting β2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent mannerMechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure.Role and regulation of MKP-1 in airway inflammation.Ligand entry and exit pathways in the beta2-adrenergic receptor.Combining inhaled glucocorticoids and long acting beta(2)-adrenoceptor agonists in asthma and COPD.Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423).Anti-inflammatory actions of phosphatidylinositol.Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells.Fast beneficial systemic anti-inflammatory effects of inhaled budesonide and formoterol on circulating lymphocytes in asthma.
P2860
Q24202303-39D49E19-271D-43B7-9732-CE049E28379AQ24234702-AAD23BDC-B5A9-457B-9488-552C49FBAE76Q24624543-F3039050-4FD2-4AAF-99D2-8F49FD6EC091Q24651941-39865A16-6A8D-4237-8959-B5F8DDCC7886Q28077040-7EAA44E0-0B22-466E-9699-C02A0131C98EQ28083987-1FAA4EF1-3977-4507-BCA4-8613D6BF2B39Q28391808-31024852-D426-4A64-B6AA-7BAB55A1FDCDQ28743191-0C42DDB7-5070-4A2C-A2CE-B107CCB17A52Q33785819-DF89CAE7-FF94-4AA3-8179-60EF8B1251A1Q34038869-74C67E74-DB74-4ED6-9A77-A8B0D2934663Q34634348-53A0E92B-593B-463B-95A1-F61F49560F3FQ34637901-23A4AD5A-5DBD-423F-8D40-11A7B884D4E3Q34903070-57FC0EFB-4111-4851-9C96-2E1AB26D7695Q35621371-7573009C-A10B-4530-B423-20EC5E69AEC4Q36110498-DB1FD408-57DF-4035-AFE1-26E88253C138Q36352557-621FF60A-0C23-4785-9CF7-E68805F77C01Q36805501-0ED822D4-E761-4F3C-8508-4366264569E1Q37578103-32421A0F-25B7-4536-814C-A4201846CBE3Q37589707-A45EFF2C-BE7B-49CD-AA23-787D6C08A40CQ37688339-39A3DE6F-80F8-496B-AE1E-ED7123CFD909Q37891137-39099799-A12D-4AB7-95B8-AA2F3A3FA98CQ37932864-07762177-2B70-4D52-9985-468C69EE3590Q38013462-0C6934FF-831D-4FA6-B11A-74B0ED3F0256Q38166604-6EA1259A-EF50-4ACD-B0EE-3620CF1DBF49Q38193172-F6CE4B53-93B1-4FD8-AB0B-DC57D5F6C2EDQ38464419-F34A1230-0DFB-4B02-8C38-BAFCB6AA36D6Q38687445-8CF9E3AF-DA1C-40F6-82E0-0A5A20A4C1A3Q38759118-67AB9DC7-BA15-41A9-8C74-722775441B61Q38915978-A068270B-B961-4B1A-9808-E07AAEF66993Q38959067-72E79BC5-1EED-4CE0-A632-A34E42C9DD8EQ38974241-A46D05E1-18F0-4804-A860-B90DF13F4579Q39960078-79EFF1BC-DC2D-45BF-8065-B86582084A13Q40447823-D2B6B502-DBCB-4F51-8DFB-BEB79928BEFBQ41365375-CED300F9-FEA2-4E59-85E0-2A8375B43AF1Q42933080-DD75CC9F-2B68-42DB-8CBC-D5736D5CE2C8Q43088106-A35A471A-F52A-493C-9881-FA5C14322045Q44358992-6543D8FE-F909-45C7-96EE-5A7322ADBEB5Q45919766-316CEF59-056A-49CE-ACD8-D5930305AD51Q46038615-BCA8F79E-DEF3-490B-AFB9-64DAEEDFF34DQ46951348-795BA314-8EEF-41C7-88D6-DF916C160884
P2860
A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A Holy Grail of asthma managem ...... cy of inhaled corticosteroids.
@ast
A Holy Grail of asthma managem ...... cy of inhaled corticosteroids.
@en
type
label
A Holy Grail of asthma managem ...... cy of inhaled corticosteroids.
@ast
A Holy Grail of asthma managem ...... cy of inhaled corticosteroids.
@en
prefLabel
A Holy Grail of asthma managem ...... cy of inhaled corticosteroids.
@ast
A Holy Grail of asthma managem ...... cy of inhaled corticosteroids.
@en
P2093
P2860
P356
P1476
A Holy Grail of asthma managem ...... cy of inhaled corticosteroids.
@en
P2093
P2860
P304
P356
10.1038/SJ.BJP.0707627
P407
P577
2007-12-10T00:00:00Z